Safety and Benefits of Modern Hormonal Contraceptives
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: closed (15 November 2021) | Viewed by 18920
Special Issue Editors
Interests: hormonal contraception; estrogen; progestin; BRCA; gynecological cancer
Interests: hormonal contraception; SARC; LARC; intrauterine device; levonoregestrel-releasing intrauterine device; progestin
Special Issue Information
Dear colleagues,
The reduction of health-related risks is an important hallmark in the field of women’s health care. This is of primary interest for contraceptive drugs, which are usually prescribed to healthy women with the sole purpose of avoiding unintended pregnancy. Therefore, the ideal contraceptive would be one that eliminates, or greatly reduces, the risk of harm and adverse events while maintaining a similar efficacy, with many additional possible health benefits for the user. With the latest evolution of contraception technology, many modern hormonal contraceptives—both short and long-acting—meet these prerequisites. The aim of this Special Issue is to highlight the latest discoveries in this broad topic, and to offer clinicians additional safety data for the use of these drugs of daily use.
Dr. Giovanni Grandi
Dr. Maria Chiara del Savio
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hormonal contraceptives
- pills
- vaginal ring
- patch
- levonorgestrel intrauterine system
- combined hormonal contraceptives
- estradiol
- ethinylestradiol
- progestin
- venous thrombo-embolism
- benefits
- bone
- dysmenorrhea
- metabolism
- lipids
- glucose
- diabetes
- cardiovascular
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
